These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Current classification of anti-arrhythmia agents]. Weirich J; Wenzel W Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787 [TBL] [Abstract][Full Text] [Related]
4. Model systems for the discovery and development of antiarrhythmic drugs. Nattel S; Duker G; Carlsson L Prog Biophys Mol Biol; 2008; 98(2-3):328-39. PubMed ID: 19038282 [TBL] [Abstract][Full Text] [Related]
5. Current clinical perspectives on antiarrhythmic drug therapy. Anderson JL Fed Proc; 1986 Jul; 45(8):2213-9. PubMed ID: 3720963 [TBL] [Abstract][Full Text] [Related]
6. New perspectives in cardiology: recent advances in antiarrhythmic drug therapy. Novotny MJ; Adams HR J Am Vet Med Assoc; 1986 Sep; 189(5):533-9. PubMed ID: 2875985 [TBL] [Abstract][Full Text] [Related]
7. [Principles for the classification of anti-arrhythmia agents in cardiac arrhythmias]. Ravens U Z Kardiol; 1992; 81 Suppl 4():119-25. PubMed ID: 1290288 [TBL] [Abstract][Full Text] [Related]
8. Current and new drugs for the treatment of arrhythmias. Auer J; Berent R; Weber T; Lassnig E; Eber B Curr Opin Investig Drugs; 2002 Jul; 3(7):1029-36. PubMed ID: 12186263 [TBL] [Abstract][Full Text] [Related]
9. [New aspects of the electrophysiologic effect of antiarrhythmic agents]. Antoni H; Weirich J Herz; 1990 Apr; 15(2):61-9. PubMed ID: 2188893 [TBL] [Abstract][Full Text] [Related]
10. Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study. Cimponeriu A; Starmer CF; Bezerianos A IEEE Trans Biomed Eng; 2003 Feb; 50(2):168-77. PubMed ID: 12665030 [TBL] [Abstract][Full Text] [Related]
11. New perspectives in cardiology: pharmacodynamic classification of antiarrhythmic drugs. Adams HR J Am Vet Med Assoc; 1986 Sep; 189(5):525-32. PubMed ID: 2875984 [TBL] [Abstract][Full Text] [Related]
12. [Antiarrhythmic agents: current situation]. Bonhorst D Rev Port Cardiol; 1995 May; 14(5):421-9, 362. PubMed ID: 7654403 [TBL] [Abstract][Full Text] [Related]
13. Basic cardiac electrophysiology and mechanisms of antiarrhythmic agents. Perry RS; Illsley SS Am J Hosp Pharm; 1986 Apr; 43(4):957-74. PubMed ID: 2871752 [TBL] [Abstract][Full Text] [Related]
14. [Ventricular tachyarrhythmia. Drug therapy and evaluation of success]. Seipel L; Kühlkamp V Z Kardiol; 1993; 82 Suppl 5():155-61. PubMed ID: 8154157 [TBL] [Abstract][Full Text] [Related]
18. Antiarrhythmic drugs: electrophysiological basis of their clinical usage. Weng JT; Smith DE; Moulder PV Ann Thorac Surg; 1986 Jan; 41(1):106-12. PubMed ID: 2417568 [TBL] [Abstract][Full Text] [Related]
19. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304 [TBL] [Abstract][Full Text] [Related]
20. Na+ channel blockers vs class III antiarrhythmic drugs in treating sustained ventricular tachycardia: reversing and preventing as different electrophysiological mechanisms. Masotti CS; Pierangeli A Panminerva Med; 1999 Dec; 41(4):295-306. PubMed ID: 10705709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]